Proteonomix (PROT.OB) notes the favorable similarity between technology involved in the Cephalon, Inc. (CEPH) transaction with Australian company Mesoblast Limited.

Michael Cohen, the Company’s founder and CEO stated, “We applaud the transaction between Cephalon and Mesoblast and take this opportunity to note that our StromaCel® bone marrow derived stem cell technology attacks similar medical problems with a different approach.”

Mr. Cohen continued, “Our StromaCel® technology is also designed to treat damage to cardiac tissue caused by myocardial infarction (MI) and we are actively seeking funding to open clinics worldwide to treat MI patients. This technology was developed in conjunction with the University of Miami where bone marrow derived stem cells are undergoing Phase I trials. We are seeking joint venture partners to give effect to this strategy.”

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix. StromaCel, Inc.’s goal is the development of therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

***************************

Crown Equity Holdings Inc. (OTCBB:CRWE) announced recently that it is expanding its business by opening another office in Pakistan. This office will be located in the city of Attock, Pakistan. This office will add an additional workforce of 25 associates to its CRWENewswire team, which will increase the company’s up to date news and world affairs from the Mid-East, Far East and Europe online news wires.

The new office in the city of Attock, as well as the office in Islamabad, will be managed by Zeeshan Shabbir.

Crown Equity Holdings is in the process of developing its Arabic language CRWENewswire site for news occurring in Pakistan and elsewhere around the world.

***************************

Fuwei Films (Holdings) Co., Ltd. (Nasdaq:FFHL) recently announced that management has become aware of a sharp increase in the Company’s stock price over the past three months, since the announcement of the settlement of the class action litigation against the Company on September 20.

Fuwei Films (Holdings) Co., Ltd., together with its subsidiaries, engages in the development, manufacture, and distribution of plastic film using the biaxial oriented stretch technique, known as BOPET film (biaxially oriented polyethylene terephthalate).

***************************

Myrexis, Inc. (Nasdaq:MYRX) recently announced it has initiated a controlled two-arm Phase 2b clinical study of Azixa (verubulin) as a front-line treatment for glioblastoma multiforme (GBM). In previous Phase 2 studies, Azixa demonstrated potent, durable antitumor responses without any additive toxicity.

Myriad Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel small molecule drugs for the treatment of diseases with high unmet need, including cancer and HIV infection.

***************************

MoSys, Inc. (NasdaqGM:MOSY) recently announced that Len Perham, President and Chief Executive Officer, and Jim Sullivan, Chief Fincial Officer, will present at the 13th Annual Needham Growth Stock Conference to be held at the New York Palace Hotel in New York, NY. Management is scheduled to present at 10:00 a.m. (Eastern Time) on Wednesday, January 12, 2011, and will available to meet with investors throughout the day. Portfolio managers and analysts who wish to meet with management at the conference should contact their Needham & Company, LLC representative or email conferences@needhamco.com.

MoSys, Inc. designs, develops, markets, and licenses embedded memory intellectual property (IP) used by the semiconductor industry and communications, networking, and storage equipment manufacturers.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services (which has expired) for Proteonomix, Inc. (PROT.OB)

Proteonomix (PROT.OB) a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on the Company’s addition to its Board of Directors. Proteonomix, Inc. is pleased to announce that Ian McNiece has been appointed to the Proteonomix Board of Directors.

In February, 2010, he was appointed to the Board of Directors of The Foundation for the Accreditation of Cellular Therapy (FACT). Founded in 1996, FACT establishes standards for high quality medical and laboratory practice in cellular therapies. It is a non-profit corporation co-founded by the International Society for Cellular Therapy (ISCT) and the American Society of Blood and Marrow Transplantation (ASBMT) for the purposes of voluntary inspection and accreditation in cellular therapy field. The major objective of FACT is to promote high quality patient care and laboratory performance in the belief that a valid accreditation must assess both clinical and laboratory aspects.

In 2000, recognizing the global impact of cord blood banking and transplantation, FACT co-developed international standards for cord blood collection, processing, testing, banking, selection and release. In 2006, FACT collaborated to establish international standards in the field of cellular therapy by international teams of experts in cellular therapy and cord blood banking fields. The standards contain the minimum guidelines for facilities and individuals performing cellular therapy product transplantation, cord blood banking, or providing support services for such activities. On-site inspections are carried out by a team of inspectors who are qualified by training and experience, have attended inspector training and who have a working knowledge of FACT. The inspection process is quality-oriented and follows the FDA’s rules for current Good Tissue Practice.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

**************************************

Global Hunter Corp. (TSX.V: BOB) (FSE:G5D) is pleased to announce that it recently completed a surface sampling program at La Corona de Cobre. The program was designed to collect surface samples from the numerous prospective shear zones. This will aid in the definition of drill targets to expand on the copper oxide mineralization.

The samples will be collected from outcrops along the entire strike lengths of the shears and have been shipped to ALS Chemex Labs in La Serena Chile for analysis. Results will be released as soon as is practical after they have been received.

These shear zones can be traced on surface for hundreds of metres, with the longest being Vino Fino, which has been mapped for over 6,000 metres. Local miners are currently extracting ore from several shear zones on the property and transporting it to Enami for processing.

The surface sample results in conjunction with previous geophysical work completed on the property, Global Hunter intends to prepare a multi-hole drill program on the shear zones scheduled to begin early 2011 as part of its ongoing evaluation of its Corona de Cobre project. In addition to sampling and drilling of the prospective shear zones at La Corona de Cobre mentioned above, The Company will continue its work on the Las Posadas resource over the coming months and will provide a summary of its progress as information becomes available.

Global Hunter’s flagship project is the La Corona de Cobre property, located 70 kilometres north of La Serena, Chile, along the Pan American Highway, within the coastal belt of the Andean Cordillera. The NI 43-101-compliant resource contains 225 million pounds of copper oxide. In addition, the Company has its Rabbit South molybdenum project in south-central British Columbia, Canada.

For More Information Go To: www.globalhunter.ca

**************************************

The Allstate Corporation (NYSE:ALL) announced the launch of Drive Wise, a voluntary program that rewards safe and low-mileage Illinois drivers with discounts of up to 30 percent. The company plans to expand Drive Wise to other states as early as Q2 2011. Consumers can learn more and sign up for the program by contacting their local Allstate agent.

The Allstate Corporation, through its subsidiaries, engages in the personal property and casualty insurance business, as well as in the life insurance, retirement, and investment products business in the United States and Canada.

**************************************

NYSE Euronext, Inc. (NYSE:NYX) will host an investor day for the professional investment community on Tuesday, March 8, 2011, at the New York Stock Exchange, 11 Wall Street, New York, NY. The day’s schedule will commence with opening remarks at 8:30a.m.will expected to conclude at approximately 12:30p.m. Presenters at the conference will include Duncan L. Niederauer, Chief Executive Officer, NYSE Euronext, and other members of the company’s executive management team.

NYSE Euronext, through its subsidiaries, provides securities listing, trading, market data products, and software and technology services worldwide. The company offers products and services in cash equities, futures, options, swaps, exchange-traded products, bonds, market data, and commercial technology solutions to issuers, investors, financial institutions, and market participants.

**************************************

Owens Corning (NYSE:OC) announced that it has reached a definitive agreement with Boral Industries Ltd. to sell its Masonry Products business. The divestiture will be in two stages. Owens Corning will sell a 50 percent stake in its Masonry Products business to Boral Industries Ltd. for $45 million at closing. The Masonry Products business will then be operated jointly until early 2014. At that time, Owens Corning will sell its remaining 50 percent stake for $45 million and may receive additional proceeds dependent upon 2013 financial performance.

Owens Corning, through its subsidiaries, provides composite and building materials systems worldwide. It operates in two segments, Composites and Building Materials.

************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has previously received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services (which has expired) for Proteonomix, Inc. (PROT.OB)

Crown Equity Holdings Inc. (CRWE.OB) has received twenty-five thousand dollars in cash from Global Hunter Corp. (TSX Venture Exchange (TSX.V:BOB) and the Frankfurt Stock Exchange (FSE:G5D)) for 30 (thirty) days of advertising, as well as for assistance in becoming a fully reporting publicly trading Bulletin Board company.

**************************************************************

___

PROTEONOMIX, INC. (PROT.OB)

PROT announced that it has filed a utility patent application for the Preparation and Use of Stromal Cells for Treatment of Cardiac Diseases.

Michael Cohen, President of PROT, stated: “This is another step in the development of our intellectual property and getting StromaCel into the commercial market. The technology covered by the patent application will reduce the cost to the patient of this type of treatment and when trials are completed and regulatory approvals are obtained we believe that the stromal cell technology we announce today will have major importance in the treatment of cardiac damage caused by heart attacks.”

Without going into proprietary details, Mr. Cohen noted that the application relates to cell line expansion that he believes represents a fundamental improvement in the efficiency of producing stem cells which should have applications far beyond the cardiac therapy to which the present application relates.

PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of PROT that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is PROT’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. PROT Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. PROT intends to create and dedicate a subsidiary to each of its technologies.

To learn more about PROT visit: http://www.proteonomix.com

*************************

Phoenix Footwear Group, Inc. (AMEX:PXG)

PXG recently announced the resignation of its Chief Executive Officer and President, Russell Hall, that became effective September 10, 2010.

PXG, headquartered in Carlsbad, California, specializes in quality comfort women’s and men’s footwear with a design focus on fitting features.

*************************

Phoenix Technologies Ltd. (Nasdaq:PTEC)

PTEC, the global leader in core system software products, services and embedded technologies, recently announced that it has successfully demonstrated the world’s first UEFI plug-in on the UEFI reference BIOS for the Intel 5 series-M chipset customer reference board.

PTEC, the leader in core system software products, services and embedded technologies, pioneers open standards and delivers innovative solutions that enable the PC industry’s top system builders and specifiers to differentiate their systems, reduce time-to-market and increase their revenues.

*************************

PhotoMedex, Inc. (Nasdaq:PHMD)

PHMD a leading supplier of advanced, clinical skincare and medical laser products for nearly a decade, recently announced the introduction of its DNA + Copper[Cu] product line, formulated and marketed by PHMD’s Neova brand.

PHMD is a leader in the development, manufacturing, and global marketing of dermatology products and techniques focused on advancing cost-effective technologies that provide patients with better outcomes and a higher quality of life.

___

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

**************************************************************

PROTEONOMIX, INC. (PROT.OB), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

****

Lucas Energy, Inc. (AMEX:LEI) an independent oil and gas company based in Houston, Texas, announced on October 1, 2010 that its joint venture operating partner, Hilcorp Energy Company, has permitted the Hagen EF No.1H well in Gonzales County, Texas. Lucas has a 15% carried (no capital cost to Lucas) working interest in this first well which is planned to be spudded by November 1, 2010. The permit is for a 4,500 foot lateral in the Eagle Ford formation.

****

Qwest Communications International Inc. (NYSE:Q) — Administrators of bankrupt fibre glass KPNQwest are demanding 4.2 billion euros ($5.7 billion) in unpaid debt from major shareholders KPN and Qwest and former executives, the administrators said on Wednesday September 29, 2010. Administrator Marcel Windt of Duch law firm Houthoff Buruma told ANP-Reuters the 2002 bankruptcy of KPQwest, which left the debt unpaid for, was caused by mismanagement and failed supervision.

A spokesman for Dutch telecoms group KPN said the company had received the subpoena and would study it. U.S. phone carrier Qwest Communications, which has agreed to be bought by telephone operator CenturyLink, declined to comment. KPNQwest, a wholesale telecoms joint venture for large corporate customers between Qwest and KPN, was listed in 1999 but went bankrupt in 2002 after the telecoms and technology bubble burst.

****

Adeona Pharmaceuticals, Inc. (AMEX:AEN) recently announced completion of 100% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer’s Disease (CopperProof-2).

Part 2 of the CopperProof-2 study is designed as a 60-subject comparator study. Alzheimer’s disease and mild cognitive impairment subjects are randomized on a 50:50 basis to receive either Zinthionein or matching placebo. After 3 and 6 months on clinical trial material, serum measurements of zinc and copper are taken and any changes in cognitive function using standard Alzheimer’s disease clinical tests are recorded.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)